• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Conatus Pharmaceuticals

edit

Conatus Pharmaceuticals is a privately-held biotechnology company focused on the development of innovative human therapeutics to treat liver disease and cancer. Their lead program, CTS-1027, is currently undergoing Phase 2 clinical trials for the treatment of Hepatitis C Virus (HCV). Conatus licensed CTS-1027 from Hoffmann-La Roche in 2006, and to date its development has been the primary focus of the Company.

Recent Milestones

edit

• 
  Conatus Pharmaceuticals received $7.5M in Series B funding. (4/12/11)
  Posted 4/12/11 at 5:26pm via msn.com
• 
  Conatus Pharmaceuticals received $20M in Series B funding. (2/11/11)
  Posted 2/12/11 at 3:52am via pharmalive.com

Videos

Screenshots

edit

Above: Conatus Pharmaceuticals
Uploaded: 2/12/11

Sources

1. Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing (pharmalive.com) [edit]
2. Conatus Pharmaceuticals Completes the Second Closing of its Series B Private Placement Financing (money.msn.com) [edit]